Long-term proton pump inhibitor use in children: A retrospective review of safety

Digestive Diseases and Sciences

Volumn 53, Issue 2, 2008, Pages 385-393

  Tolia, V ^a,b   Boyer, K ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b NONE   (United States)

Author keywords

Children; Gastrin; Gastritis; Long term use; Proton pump inhibitors; Safety

Indexed keywords

CYANOCOBALAMIN; ESOMEPRAZOLE; GASTRIN; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADOLESCENT; ARTICLE; CHILD; CHILD CARE; CHILD SAFETY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTRITIS; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; LIVER FUNCTION TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; STOMACH BIOPSY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; CHILD; CHILD, PRESCHOOL; ESOPHAGITIS; FEMALE; GASTRINS; HUMANS; LIVER FUNCTION TESTS; MALE; OMEPRAZOLE; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; VITAMIN B 12;

EID: 38649091066     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-9880-7     Document Type: Article

References (48)

1. Nelson SP, Chen EH, Syniar GM, Christoffel KK (1997) Prevalence of symptoms of gastroesophageal reflux during infancy. A pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 151:569-572
2. Nelson SP, Chen EH, Syniar GM, Christoffel KK (1998) One-year follow-up of symptoms of gastroesophageal reflux during infancy. Pediatrics 102(6):E67. http://www.pediatrics.org/cgi/content/full/102/6/c67
3. Nelson SP, Chen EH, Syniar GM, Christoffel KK, for the Pediatric Practice Research Group (2000) Prevalence of symptoms of gastroesophageal reflux during childhood: a pediatric practice-based survey. Arch Pediatr Adolesc Med 54:150-154
4. Ramesh P, Santiago M, Schmidt K, Gunasekaran TS (2001) Prevalence of gastroesophageal reflux disease symptoms in an African American predominant adolescent high school population. J Pediatr Gastroenterol Nutr 33:A194
5. Ramesh P, Braden D, Dey S, Gunasekaran TS (2002) Prevalence of gastroesophageal reflux disease (GERD) symptoms in a Caucasian predominant adolescent population. Gastroenterology 122:A213
6. Waring JP, Feiler MJ, Hunter JG, Smith CD, Gold BD (2002) Childhood gastroesophageal reflux symptoms in adult patients. J Pediatr Gastroenterol Nutr 35:334-338
7. El-Serag HB, Gilger M, Carter J, Genta RM, Rabeneck L (2004) Childhood GERD is a risk factor for GERD in adolescents and young adults. Am J Gastroenterol 100:806-812
8. DiBaise J, Young R, Ward B, Lyden E, Vanderhoof J (2005) A retrospective, case-control study of the natural history of pediatric GERD. Gastroenterology (4 Suppl 2):Abstract M1070
9. Hirschowitz BI, Simmons J, Mohnen J (2005) Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol 3(1):39-48
10. Tolia V, Ferry G, Gunasekaran T, Huang B, Keith R, Book L (2002) Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 35:S308-S318
11. Hassall E, Israel D, Shepherd R, Radke M, Dalvag A, Skold B, Junghard O, Lundborg P (2000) Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. J Pediatr 137:800-807
12. Huang J-Q, Hunt RH (1998) Meta-analysis of comparative trials for healing erosive esophagitis with proton pump inhibitors and H2-receptor antagonists. Gastroenterology 114:A154
13. Gunasekaran T, Gupta S, Gremse D, Karol M, Pan WJ, Chiu YL, Keith R, Fitzgerald J (2002) Lansoprazole in adolescents with gastroesophageal reflux disease. Pharmacokinetics, pharmcodynamics, symptom relief efficacy and tolerability. J Pediatr Gastroenterol Nutr 35(Suppl 4):S327-S335
14. Fiedorek S, Tolia V, Gold BD, Huang B, Stolle J, Lee C, Gremse D (2005) Efficacy and safety of lansoprazole in adolescents with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 40(3):319-327
15. Metz DC (2004) Managing gastroesophageal reflux disease for the lifetime of the patient: evaluating the long-term options. Am J Med 117(5A):49S-55S
16. Onimoe GI, Tolia V, Thomas R (2005) Clinical presentation and long term outcome of gastroesophageal reflux disease in children and adolescents. J Pediatr Gastroenterol Nutr 41(4):A34
17. Wang K, Lin HJ, Perng CL, Tseng GY, Yu KW, Chang FY, Lee SD (2004) The effect of H2-receptor antagonist and proton pump inhibitor on microbial proliferation in the stomach. Hepatogastroenterology 51(59):1540-1543
18. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB (2004) Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292(16):1955-1960
19. Canani RB, Cirillo P, Roggero P et al. (2006) Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 117(5):e817-e820
20. Klinkenberg-Knol EC, Nelis F, Dent J, Snel P, Mitchell B, Prichard P, Lloyd D, Havu N, Frame MH, Roman J, Walan A (2000) Long-term study group long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa. Gastroenterology 118:661-669
21. Israel DM, Hassall E (1998) Omeprazole and other proton pump inhibitors: pharmacology, efficacy, and safety, with special reference to use in children. J Pediatr Gastroenterol Nutr 27:568-579
22. Andersson T, Hassall E, Lundborg P, Shepherd R, Radke M, Marcon M, Dalvag A, Martin S, Behrens R, Koletzko S, Becker M, Drouin E, Gothberg G (2000) Pharmacokinetics of orally administered omeprazole in children: International Pediatric Omeprazole Pharmacokinetic Group. Am J Gastroenterol 95:3101-3106
23. Hassall E, El-Serag H, Kerr W (2005) Continuous use of proton pump inhibitors in children up to 11 yrs duration. Gastroenterology (4 Suppl 2): Abstract T1669
24. SAS Institute (2001) SAS 8.2. SAS Institute, Cary
25. Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, Mitchell B, Beveridge BR, Laurence BH, Gibson GG (1988) Healing and relapse of severe peptic oesophagitis after treatment with omeprazole. Gastroenterology 95(4):903-912
26. Dixon MF, Genta RM, Yardley JH, Correa P (1996) Classification and grading of gastritis. Am J Surg Pathol 20:1161-1181
27. Marchetti F, Gerarduzzi T, Ventura A (2003) Proton pump inhibitors in children: a review. Dig Liver Dis 35:738-746
28. Bohmer CJ, Niezen-de Boer RC, Klinkenberg-Knol EC, Meuwissen SG (1998) Omeprazole: therapy of choice in intellectually disabled children. Arch Pediatr Adolesc Med 152(11):1113-1118
29. DeVault KR, Castell DO (2005) Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100(1):190-200
30. Pounder R, Smith J (1990) Drug-induced changes of plasma gastrin concentration. Gastroenterol Clin North Am 19:141-153
31. Mattsson H, Havu N, Brautigam J, Carlsson K, Lundell L, Carlsson E (1991) Parietal gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffin-like cell carcinoids in the rat. Gastroenterology 100:311-319
32. Freston JW, Borch K, Brand SJ, Carlsson E, Creutzfeldt W, Hakanson R, Olbe L, Solcia E, Walsh JH, Wolfe MM (1995) Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells. A review and analysis. Dig Dis Sci 40(2 Suppl):50S-62S
33. Pashankar DS, Israel DM, Jevon GP, Buchan AM (2001) Effect of long-term omeprazole treatment on antral G and D cells in children. J Pediatr Gastroenterol Nutr 33(5):537-542
34. Singh P, Indaram A, Greenberg R, Visvalingam V, Bank S (2000) Long term omeprazole therapy for reflux esophagitis: follow-up in serum gastrin levels, EC cell hyperplasia and neoplasia. World J Gastrenterol 6:789-792
35. Hage E, Hendel L, Gustafsen J, Hendel J (2003) Histopathology of the gastric oxyntic mucosa in two different patient groups during long-term treatment with omeprazole. Eur J Gastroenterol Hepatol 15(7):781-789
36. Laine L, Ahnen D, McClain C, Solcia E, Walsh JH (2000) Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 14(6):651-668
37. Pashankar DS, Israel DM (2002) Gastric polyps and nodules in children receiving long-term omeprazole therapy. J Pediatr Gastroenterol Nutr 35(5):658-662
38. Graffner H, Singh G, Chaudry I, Milsom JW (1992) Omeprazole-induced hypergastrimenia does no influence growth of colon carcinoma. Dig Dis Sci 37(4):485-489
39. Pinson DM, Havu N, Sztern MI, Mattsson H, Looney GA, Kimler BF, Hurwitz A (1995) Drug-induced hypergastrinemia: absence of trophic effects on colonic carcinoma in rats. Gastroenterology 108(4):1068-1074
40. Litalien C, Theoret Y, Faure C (2005) Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet 44(5):441-466
41. de Korwin JD, Ducrotte P, Vallot T (2004) New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases? Presse Med 33(11):746-754
42. Robinson M, Horn J (2003) Clinical pharmacology of proton pump inhibitors: what the practicing physician needs to know. Drugs 63(24):2739-2754
43. Ruscin JM, Page RL, Valuck RJ (2002) Vitamin B (12) deficiency associated with histamine (2)-receptor antagonists and a proton-pump inhibitor. Ann Pharmacother 36(5):812-816
44. Valuck RJ, Ruscin JM (2004) A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 57(4):422-428
45. Howden CW (2000) Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol 30(1):29-33
46. Force RW, Meeker AD, Cady PS, Culbertson VL, Force WS, Kelley CM (2003) Ambulatory care increased vitamin B12 requirement associated with chronic acid suppression therapy. Ann Pharmacother 37(4):490-493
47. ter Heide H, Hendriks HJ, Heijmans H, Menheere PP, Spaapen LJ, Bakker JA, Forget PP (2001) Are children with cystic fibrosis who are treated with a proton-pump inhibitor at risk for vitamin B(12) deficiency? J Pediatr Gastroenterol Nutr 33(3):342-345
48. Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296(24):2947-2953